2022-24016. HISA Anti-Doping and Medication Control Rule; Correction  

  • Start Preamble

    AGENCY:

    Federal Trade Commission.

    ACTION:

    Notice of Horseracing Integrity and Safety Authority (HISA) proposed rule; correction.

    SUMMARY:

    The Federal Trade Commission (“Commission”) published a document in the Federal Register of October 28, 2022, concerning the Anti-Doping and Medication Control proposed rule submitted by the Horseracing Integrity and Safety Authority. The Authority alerted the Commission that its submission contained an incorrect number. The Commission is issuing this correction to reflect the corrected number.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Austin King, Associate General Counsel for Rulemaking, 202-326-3166, aking3@ftc.gov, Office of the General Counsel, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Correction

    In FR Doc. 2022-22970 appearing at 87 FR 65292 in the Federal Register of Friday, October 28, 2022, in the table on page 65365, in the entry for “ketoprofen,” change the first sentence of the final column, which currently reads [4 ng/mL in serum or plasma.], to read [2 ng/mL in serum or plasma.], which is the amount the Authority intended to submit but did not because of a typographical error.

    Start Signature

    Dated: October 31, 2022.

    April J. Tabor,

    Secretary.

    End Signature End Supplemental Information

    [FR Doc. 2022-24016 Filed 11-3-22; 8:45 am]

    BILLING CODE 6750-01-P

Document Information

Published:
11/04/2022
Department:
Federal Trade Commission
Entry Type:
Notice
Action:
Notice of Horseracing Integrity and Safety Authority (HISA) proposed rule; correction.
Document Number:
2022-24016
Pages:
66705-66705 (1 pages)
Docket Numbers:
File No. P222100
PDF File:
2022-24016.pdf
Supporting Documents:
» HISA Anti-Doping and Medication Control Rule; Correction
» Exhibit B - Supporting Documents on which HISA Relied.pdf1
» Exhibit A - Stakeholder Comments on HISA ADMC Proposed Rules (002)
» HISA Anti-Doping and Medication Control Rule